TFF Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- TFF Pharmaceuticals, Inc. (TFFP) is a clinical-stage biopharmaceutical company that develops and commercializes innovative drug products using its proprietary Thin Film Freezing (TFF) technology platform. The company manufactures novel dry powder formulations of biologics, small molecules, vaccines and antibiotics for pulmonary delivery via inhalation; key product candidates include TFF VORI (voriconazole inhalation powder) for invasive pulmonary aspergillosis, TFF TAC (tacrolimus inhalation powder) for lung transplant rejection prevention, TFF SILD (sildenafil inhalation powder) for pulmonary arterial hypertension, and TFF AMX (amoxicillin inhalation powder) for melioidosis treatment. TFF Pharmaceuticals offers contract development and manufacturing organization (CDMO) services leveraging the TFF platform to third-party pharmaceutical companies for aerosol drug formulation enhancement. Founded in 2014 and headquartered in Austin, Texas, the company operates primarily in the United States with a focus on the biopharmaceutical industry, targeting patients with respiratory diseases, transplant recipients, and those requiring localized lung therapies. Recent developments include advancing clinical trials for lead candidates such as the Phase 2 VORI-PAH study for pulmonary arterial hypertension in 2025 and ongoing FDA interactions for TFF TAC following positive preclinical data; the company also expanded its pipeline through technology licensing agreements and received non-dilutive grant funding for antibiotic programs in late 2024.
TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration
TFF Pharmaceuticals Announces It Will Wind Down Operations
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
3 52-Week-Low Losers Ready to Become Big-Time Stock Winners
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs